NCCN 2022 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™
The management of cancer is constantly evolving through the introduction of new advances related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide hematology/oncology nurses with practical information that can be implemented in the practice setting.
This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.
The goal of this activity is to ensure that hematology/oncology nurses, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with hematologic malignancies. Following this program, participants should be able to:
- Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review new, emerging, and novel treatment and supportive care strategies, and incorporate these into the management of patients with hematologic malignancies.
Session Learning Objectives
Implementation of a Hematology Outpatient Sepsis Alert Protocol
- Discuss the steps involved to create a system of early recognition of sepsis in an outpatient hematology clinic.
- Explain the tools and resources that could be used for standardized educational pathways to help identify patients at risk for sepsis.
- Review how implementation of sepsis protocols and data obtained impact quality, cost and patient satisfaction.
Palliative Care and Hematologic Malignancies: Can They Co-Exist?
- Identify barriers to incorporating palliative care with hematologic malignancy patients.
- Describe the benefits of palliative care as part of the care team for hematologic malignancy patients.
- Discuss the efficacy of symptom management when palliative care is part of the care team for patients with hematologic malignancies.
Key Assessment and Evaluation Strategies After CAR T-Cell Therapy
- Define CAR T-cell therapies and their uses in clinical practice.
- Describe the mechanism of action in the treatment of disease and how this relates to adverse effects.
- Understand the assessment and strategies for the prevention and management of CAR T-cell adverse events.
Updates in the Management of Graft-Versus-Host Disease
- Identify risks for graft-versus-host disease (GVHD) after hematopoietic cell transplantation.
- Describe presentation and assessment for GVHD.
- Describe management of GVHD (acute vs. chronic).
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Shelly Brown, MS, APRN-CNS, OCN, AOCNS
Nancy Cruz Sitner, ANP-BC, BMTCN
Jennifer Peterson, MSN, RN, OCN, BMTCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Stephany Rodriguez, RN, MS, NP
Genentech, Inc.: Product/Speakers Bureau
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this educational activity for a maximum of 3 contact hours. This program offers 1 pharmacotherapeutic contact hour for nurses.
- 3.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 3.00 Participation
Credit claiming is now open. Please log in with the email address you used for event registration.
CE credit should be claimed for the Forum as a whole, not session by session. You may only claim credit for the forum one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note: you have access to all session recordings for 60 days after the live event).